The SDC1 antibody targets syndecan-1 (SDC1), a transmembrane heparan sulfate proteoglycan belonging to the syndecan family. SDC1 plays critical roles in cell-matrix interactions, cell adhesion, migration, and signaling by binding extracellular ligands like growth factors, cytokines, and components of the extracellular matrix. It is expressed in epithelial cells, plasma cells, and certain cancer cells, and its dysregulation is linked to cancer progression, inflammation, and wound healing. In oncology, SDC1 is studied as a biomarker in multiple myeloma, breast cancer, and other malignancies, where its overexpression or shedding correlates with tumor aggressiveness, metastasis, and poor prognosis. The SDC1 antibody is widely used in research to detect SDC1 expression via techniques such as immunohistochemistry, flow cytometry, and Western blot. It helps elucidate SDC1's functional roles, including its dual activity in tumor suppression (via cell adhesion) and promotion (via soluble ectodomain release). Commercial SDC1 antibodies are validated for specificity against epitopes in the extracellular or intracellular domains, with clones like B-B4 and MI15 commonly employed. Studies also explore SDC1's therapeutic potential, such as antibody-drug conjugates targeting SDC1-positive cancers.